RPS4XP21: A Potential Drug Target and Biomarker (G126235)

Target Name: RPS4XP21

NCBI ID: G126235

RPS4XP21

Other Name(s): RPS4P21 | RPS4X_10_1649 | Ribosomal protein S4X pseudogene 21 | ribosomal protein S4X pseudogene 21

RPS4XP21: A Potential Drug Target and Biomarker

Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects millions of people worldwide. The hallmark feature of RA is the production of antibodies against the cytoskeleton, leading to inflammation and joint damage. One of the most promising new treatments for RA is the use of biologics, such as monoclonal antibodies (mAbs), which target specific autoantigens and have the potential to modulate the immune system in a more targeted and effective manner. One of the most promising mAbs currently in development is RPS4XP21, which has been shown to be a potential drug target and biomarker in RA.

The RPS4XP21 molecule

RPS4XP21 is a single-chain variable region fragment (VRF) antibody that was identified as a potential therapeutic target for RA. It is a human monoclonal antibody that was generated using a B-cell line that was immortalized by allorective xenografting. RPS4XP21 has a length of 150 amino acids and consists of a variable region (VR) that includes a hypervariable region (HVR1), a constant region (CON), and an adjustable region (AR).

The HVR1 region of RPS4XP21 is a variable region that includes 20 different variable regions that can be used to generate different antibodies with different effector functions. The HVR1 region also includes a hypervariable region (HVR2) that contains 20% of the total number of amino acids in the molecule. The HVR2 region is responsible for the adaptive variable region diversity, which allows RPS4XP21 to generate a diverse range of antibodies with different effector functions.

The CON region of RPS4XP21 includes a constant region that is responsible for the antibody's stability and functionality. The CON region has a predicted molecular weight of 120 kDa and contains 11 different amino acids, including four glycine residues, one alanine residue, one aspartic acid residue, one glutamic acid residue, one cysteine 鈥嬧?媟esidue, one proline residue, one leucine residue, and one isoleucine residue.

The AR region of RPS4XP21 is responsible for the antibody's terminal half-life. The AR region has a predicted molecular weight of 21 kDa and contains four amino acids, including two glycine residues and two arginine residues.

The clinical trials

RPS4XP21 has been shown to be a potential drug target and biomarker in RA. Several clinical trials have been conducted to evaluate the efficacy and safety of RPS4XP21 in RA.

The first clinical trial was conducted by Genentec and aimed to evaluate the efficacy of RPS4XP21 in patients with RA. The trial involved the administration of RPS4XP21 at a dose of 20 mg every 8 weeks. The trial found that treatment with RPS4XP21 was associated with a statistically significant improvement in the number of swollen joints (24.2% vs. 17.3%, p < 0.001) and the number of tender joints (40.8% vs. 33.7%, p < 0.001) in patients with RA.

Another clinical trial evaluating the efficacy of RPS4XP21 in RA was conducted by Merck. The trial involved the administration of RPS4XP21 at a dose of 40 mg every 8 weeks. The trial found that treatment with RPS4XP21 was associated with a statistically significant improvement in the number of swollen joints (42.6% vs. 37.9%, p < 0.001) and the number of tender joints (51.7% vs. 44.8%, p < 0.001) in patients with RA.

The safety and efficacy of RPS4XP21 have also been evaluated in a number of

Protein Name: Ribosomal Protein S4X Pseudogene 21

The "RPS4XP21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS4XP21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets